Patients in distributive shock appear to have a lower risk for atrial fibrillation when vasopressin is added to catecholamine vasopressors, but its effect on other outcomes are mixed, according to a ...
Giapreza, a vasoconstrictor, increases blood pressure through increased aldosterone release La Jolla Pharmaceutical announced the availability of Giapreza (angiotesin II) injection for intravenous (IV ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Among patients ...
One in eight patients hospitalized with COVID-19 develop some form of shock, according to the American Heart Association’s COVID-19 Cardiovascular Disease Registry. And regardless of whether the shock ...
Company watchers differed over the half-empty, half-full glass of a $125 million financing agreement signed by La Jolla Pharmaceutical Co. (LJP) with Healthcare Royalty Partners (HCR) for Giapreza ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback